Bristol-Myers Squibb (NYSE:BMY) shares sold by O Dell Group LLC

O Dell Group LLC trimmed its stake in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 4.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 7,043 shares of the biopharmaceutical company’s stock after selling 324 shares during the quarter. O Dell Group LLC’s holdings in Bristol-Myers Squibb were worth $361,000 at the end of the most recent quarter.

A number of other institutional investors have recently modified their positions in the stock. Norges Bank acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at $1,560,524,000. Van ECK Associates Corp grew its position in shares of Bristol-Myers Squibb by 792.6% in the fourth quarter. Van ECK Associates Corp now owns 4,030,939 shares of the biopharmaceutical company’s stock valued at $206,828,000 after buying an additional 3,579,324 shares during the period. Primecap Management Co. CA grew its position in shares of Bristol-Myers Squibb by 14.6% in the fourth quarter. Primecap Management Co. CA now owns 23,534,378 shares of the biopharmaceutical company’s stock valued at $1,207,549,000 after purchasing an additional 2,998,228 shares during the period. Pacer Advisors Inc. increased its position in shares of Bristol-Myers Squibb by 48.0% in the fourth quarter. Pacer Advisors Inc. now owns 7,830,948 shares of the biopharmaceutical company’s stock valued at $401,806,000 after purchasing an additional 2,540,360 shares during the period. Finally, Franklin Resources Inc. raised its position in shares of Bristol-Myers Squibb by 36.7% in the fourth quarter. Franklin Resources Inc. now owns 9,357,199 shares of the biopharmaceutical company’s stock valued at $480,118,000 after buying an additional 2,510,134 shares during the period. 76.41% of the shares are owned by institutional investors and hedge funds.

Wall Street analysts are predicting an increase

A number of equities research analysts have issued reports on BMY shares. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 23rd. BMO Capital Markets cut their price target on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research report on Friday, April 26th. Wells Fargo & Company upped their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. Finally, Barclays reduced their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research report on Friday, the 26th April. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $60.00, based on data from MarketBeat.com.

Get the latest stock report on BMY

Bristol-Myers Squibb trade down 2.2%

NYSE:BMY opened at $41.46 on Friday. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99, and a current ratio of 1.11. Bristol-Myers Squibb has a one year low of $39.91 and a one year high of $66.38. The company’s 50-day simple moving average is $44.70, and its 200-day simple moving average is $48.79. The stock has a market cap of $84.04 billion, a price-to-earnings ratio of -13.37, a price-to-earnings-growth ratio of 14.41 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMY – Get Your Free Report ) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The firm had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. In the same quarter last year, the firm posted earnings of $2.05 per share. Bristol-Myers Squibb’s revenue for the quarter was up 4.7% compared to the same quarter last year. As a group, sell-side analysts predict that Bristol-Myers Squibb will post 0.59 earnings per share for the current fiscal year.

About Bristol-Myers Squibb

(Free report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic and neuroscience. The company’s products include Eliquis for reducing the risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anticancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Read more

Get news and reviews for Bristol-Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.